Ipca Laboratories reported quarterly revenues of Rs. 2,355 crore, a 16% year-on-year increase, with a profit after tax of Rs. 245 crore, up 39%. The company’s EBITDA rose to Rs. 441 crore, reflecting a 22% growth. Strategic investments and regulatory approvals are expected to drive future growth, with a target price of Rs. 1765.